Purple Biotech (PPBT) Cash from Operations (2014 - 2026)

Purple Biotech (PPBT) has reported Cash from Operations for 12 consecutive years, with -$2.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations fell 62.11% year-over-year to -$2.5 million in Q2 2026; TTM through Jun 2026 was -$7.8 million, a 12.15% increase from a year earlier, with the FY2025 full-year figure at -$5.7 million, up 60.63% from the prior year.
• Cash from Operations was -$2.5 million for Q2 2026 at Purple Biotech, up from -$3.1 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$1.1 million in Q3 2025 and troughed at -$6.1 million in Q1 2023.
• A 5-year average of -$3.5 million and a median of -$3.6 million in 2022 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations surged 67.62% in 2025 and plunged 62.11% in 2026, its largest moves.
• Over 5 years, Cash from Operations stood at -$4.2 million in 2022, then fell by 18.22% to -$5.0 million in 2023, then surged by 59.57% to -$2.0 million in 2024, then surged by 47.02% to -$1.1 million in 2025, then slumped by 134.58% to -$2.5 million in 2026.
• The last three Cash from Operations figures came in at -$2.5 million (Q2 2026), -$3.1 million (Q1 2026), and -$1.1 million (Q4 2025), per Business Quant data.